[HTML][HTML] Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory …
Journal of Clinical Oncology, 2012•ncbi.nlm.nih.gov
Purpose BCL2 overexpression is a hallmark of chronic lymphocytic leukemia (CLL). The
novel BH3 mimetic navitoclax (ABT-263) specifically inhibits BCL2 and related proteins BCL-
x l and BCL-w, potently inducing apoptosis of CLL cells in vitro. A phase I trial in patients
with CLL was conducted to evaluate the safety, pharmacokinetics, and biologic activity of
oral navitoclax.
novel BH3 mimetic navitoclax (ABT-263) specifically inhibits BCL2 and related proteins BCL-
x l and BCL-w, potently inducing apoptosis of CLL cells in vitro. A phase I trial in patients
with CLL was conducted to evaluate the safety, pharmacokinetics, and biologic activity of
oral navitoclax.
Abstract
Purpose
BCL2 overexpression is a hallmark of chronic lymphocytic leukemia (CLL). The novel BH3 mimetic navitoclax (ABT-263) specifically inhibits BCL2 and related proteins BCL-x l and BCL-w, potently inducing apoptosis of CLL cells in vitro. A phase I trial in patients with CLL was conducted to evaluate the safety, pharmacokinetics, and biologic activity of oral navitoclax.
ncbi.nlm.nih.gov
